Table 4.

Death from Lung Cancer (Cumulative %) by Randomization Group and Selected Baseline Characteristics

	CEE+MPA		Placebo		HR	(95% CI)	P-value for Interaction
	N	(%)	N	(%)
Entire WHI Study Period
Age at screening, y							0.23
50–59	13	(0.46%)	12	(0.45%)	1.02	(0.47, 2.24)
60–69	35	(0.91%)	16	(0.44%)	2.00	(1.11, 3.62)
70–79	25	(1.38%)	12	(0.68%)	2.00	(1.01, 3.99)
Prior hormone use							0.65
Never	56	(0.89%)	29	(0.48%)	1.83	(1.17, 2.86)
Past	14	(0.84%)	8	(0.50%)	1.53	(0.64, 3.69)
Current	3	(0.54%)	3	(0.61%)	1.07	(0.22, 5.34)
Prior E+P use							0.54
Never	65	(0.93%)	33	(0.49%)	1.86	(1.22, 2.82)
Past	5	(0.49%)	4	(0.42%)	0.89	(0.22, 3.61)
Current	3	(0.60%)	3	(0.68%)	1.10	(0.22, 5.46)
Smoking							0.77
Never	9	(0.22%)	4	(0.10%)	2.09	(0.64, 6.81)
Past	32	(0.95%)	16	(0.51%)	1.89	(1.04, 3.45)
Current	30	(3.41%)	20	(2.39%)	1.50	(0.85, 2.64)

Cumulative % = % cumulative risk for death from lung cancer over entire 7.9 year (mean) study period HRs, 95% CIs and p-values are from Cox proportional hazards models stratified according to age, prior lung cancer, and DM trial randomization assignment.

P-value is from a Wald Chi-square test for the interaction between the given characteristic and E+P trial randomization arm.